1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Pfizer Inc.

Pfizer Inc.

PFE.NE
Pfizer Inc.CN flagCBOE CA
10.57
CAD
-0.42
- -
176.97BMarket Cap
Pfizer Inc.
PFE.NE
(CBOE CA)

Recent

price

10.57

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.75
2.65
2.49
2.57
2.65
2.69
2.95
2.99
2.36
2.49
2.55
4.93
6.13
3.58
3.81
3.74
3.78
Revenue per Share
0.35
0.43
0.66
1.1
0.49
0.38
0.4
1.21
0.64
0.98
0.56
1.33
1.9
0.13
0.48
0.46
0.45
Basic EPS, GAAP
0.42
0.8
0.7
0.81
0.83
0.73
0.79
0.83
0.79
0.62
0.71
1.81
1.58
0.29
0.59
0.54
0.57
Free Cash Flow per Basic Share
0.26
0.27
0.3
0.33
0.35
0.38
0.41
0.44
0.46
0.49
0.52
0.53
0.54
0.56
0.57
0.58
0.58
Dividend per Share
1.82
2.03
2.5
3.5
3.89
3.98
4.03
4.88
5.21
5.98
5.55
6.3
7.64
7.15
7.03
6.88
7.03
Book Value per Share
-0.56
-0.57
-0.33
-0.27
-0.3
-1.3
-2.64
-1.88
-1.44
-1.14
-0.88
0.19
0.07
-2.61
-2.12
-2.28
-2
Tangible Book Value per Share
23,664
23,019
21,915
20,063
18,688
18,187
17,931
17,580
17,292
16,399
16,358
16,494
16,514
16,617
16,679
16,735
16,748
Basic Weighted Avg Shares
65,165
61,035
54,657
51,584
49,605
48,851
52,824
52,546
40,825
40,905
41,651
81,288
101,175
59,554
63,627
62,579
63,314
Sales/Revenue/Turnover
25.41
27.54
31.24
31.73
27.21
26.56
25.95
26.78
16.48
17.87
22.84
29.16
37.67
7.42
23.48
27.82
27.24
Operating Margin (%)
8,399
9,026
7,655
6,410
5,537
5,157
5,757
6,269
6,150
5,755
4,681
5,191
5,064
6,290
7,013
6,592
6,587
Depreciation Expense
8,257
10,009
14,570
22,003
9,135
6,960
7,215
21,308
11,153
16,026
9,159
21,979
31,372
2,119
8,031
7,771
7,490
Net Income, GAAP
12.17
31.54
19.76
27.4
25.49
22.2
13.45
- -
- -
5.15
5.26
7.62
9.58
- -
- -
- -
4.86
Effective Tax Rate (%)
12.67
16.4
26.66
42.65
18.42
14.25
13.66
40.55
27.32
39.18
21.99
27.04
31.01
3.56
12.62
12.42
11.83
Profit Margin (%)
31,859
31,908
35,645
32,878
34,008
14,405
7,834
10,714
18,068
-4,501
9,147
17,022
9,121
-4,461
7,363
5,914
8,474
Working Capital
38,410
34,926
31,036
30,462
31,541
27,446
30,399
32,666
32,429
34,650
35,571
34,757
31,925
60,499
56,703
60,807
59,840
LT Debt
88,265
82,621
81,678
76,620
71,622
64,998
59,840
71,656
63,758
63,447
63,473
77,462
95,916
89,288
88,497
86,775
90,404
Total Equity
9.82
9
11.32
10.19
9.07
9.57
11.67
- -
- -
6.29
8.3
20.13
27.89
- -
- -
- -
10.54
Return on Invested Capital (%)
11.03
12.8
17.64
23
9.34
7.15
7.33
- -
- -
12.45
7.53
17.1
21.47
- -
- -
- -
5.5
Return on Capital (%)
19.65
22.28
28.75
35.24
12.79
9.59
9.97
26.97
12.69
17.03
9.69
22.57
27.28
1.73
6.8
6.69
6.3
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
4,303
3,154
3,890
LT Borrowings
56,545
60,807
59,840
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5,686
5,686
5,699
Market Capitalization
138,964
137,318
151,830

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
46,924
42,898
42,822
Cash, Cash Equivalents & STI
14,984
13,596
13,075
Accounts Receivable, Net
14,260
11,874
12,585
Inventories
11,468
10,654
10,667
Total Current Liabilities
36,596
36,984
34,348
Payables & Accruals
8,823
10,788
7,636
ST Debt
4,303
3,154
3,890
Deferred Revenue
924
784
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.65%
7.22%
-1.95%
Free Cash Flow
15.28%
31.94%
-7.73%
Net Income, GAAP
51.74%
73.04%
-3.24%
Sales/Revenue/Turnover
7.1%
16.73%
-1.65%
Total Cash Common Dividend
3.49%
2.97%
2.72%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
14,878
13,283
17,701
17,764
63,627
2025
13,715
14,653
16,654
17,557
62,579
2026
14,450
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.19
- -
0.27
0.02
0.48
2025
0.18
0.17
- -
-0.1
0.46
2026
0.16
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.14
0.14
0.14
0.57
2025
0.15
0.15
- -
0.15
0.58
2026
0.15
- -
- -
- -
- -
Similar Companies
Grifols, S.A. (GRF.MC)
Biogen Inc. (IDP.DE)
Chugai Pharmaceutical Co., Ltd. (4519.T)
PharmGen Science, Inc. (004720.KS)
PT Kalbe Farma Tbk. (PTKFF)
GSK plc (GS7.DE)
Business
Pfizer Inc. is a leading global biopharmaceutical corporation engaged in the discovery, development, production, and worldwide commercialization of innovative healthcare solutions. The company's diverse portfolio includes a wide array of prescription medicines and vaccines spanning critical therapeutic areas across the United States and international markets. Its offerings encompass vital treatments and preventative measures within areas such as internal medicine, addressing cardiovascular metabolic conditions and migraine relief with products like Eliquis, Nurtec ODT/Vydura, and Zavzpret. In infectious diseases, the company provides vaccines and treatments for unmet medical needs, exemplified by the Prevnar family, Abrysvo, Comirnaty, and Paxlovid, alongside other mRNA and antiviral innovations. The company also delivers crucial therapies for chronic immune and inflammatory diseases, rare conditions including amyloidosis, hemophilia, endocrine disorders, and sickle cell disease, through biosimilars and specialized medicines such as the Vyndaqel family, Litfulo, Velsipity, and Genotropin. Oncology remains a significant focus, with a robust pipeline and offerings across breast, prostate, lung, and other cancers, featuring treatments like Ibrance, Xtandi, Padcev, and Elrexfio, particularly strengthened by the recent integration of antibody-drug conjugates. Additionally, Pfizer supplies sterile injectables and anti-infective medications. Beyond its product lines, the company operates in contract development and manufacturing, supplying specialty active pharmaceutical ingredients. Pfizer distributes its comprehensive range of products to a broad network that includes wholesalers, retail pharmacies, hospitals, clinics, government health organizations, and individual medical practices. The company maintains strategic alliances with various pharmaceutical leaders, including Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE, to advance its research and commercialization efforts. Founded in 1849, Pfizer Inc. is headquartered in New York, New York.